請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72014
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林芯?(Shin-Yu Lin) | |
dc.contributor.author | Chien-Wen Yang | en |
dc.contributor.author | 楊茜雯 | zh_TW |
dc.date.accessioned | 2021-06-17T06:19:10Z | - |
dc.date.available | 2020-10-03 | |
dc.date.copyright | 2018-10-03 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-20 | |
dc.identifier.citation | 1. Lin, P.-C., et al., The risk factors for gestational diabetes mellitus: A retrospective study. Midwifery, 2016. 42: p. 16-20.
2. Garrison, A., Screening, diagnosis, and management of gestational diabetes mellitus. Am Fam Physician, 2015. 91(7): p. 460-7. 3. Lin, C.H., et al., Using the 100-g oral glucose tolerance test to predict fetal and maternal outcomes in women with gestational diabetes mellitus. Chang Gung Med J, 2009. 32(3): p. 283-9. 4. Schwartz, N., et al., Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence. Scientific Reports, 2018. 8(1): p. 6350. 5. Montazeri, S., S. Nalliah, and A.K. Radhakrishnan, Is there a genetic variation association in the IL-10 and TNF alpha promoter gene with gestational diabetes mellitus? Hereditas, 2010. 147(2): p. 94-102. 6. Gestational Diabetes Mellitus. Diabetes Care, 2004. 27(suppl 1): p. s88-s90. 7. Catalano, P.M., et al., Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol, 1991. 165(6 Pt 1): p. 1667-72. 8. Harreiter, J., et al., IADPSG and WHO 2013 Gestational Diabetes Mellitus Criteria Identify Obese Women With Marked Insulin Resistance in Early Pregnancy. Diabetes Care, 2016. 39(7): p. e90-2. 9. Barbour, L.A., et al., Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care, 2007. 30 Suppl 2: p. S112-9. 10. Alfadhli, E.M., Gestational diabetes mellitus. Saudi Med J, 2015. 36(4): p. 399-406. 11. Petersen, J.S., et al., GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. Diabetologia, 1996. 39(11): p. 1329-33. 12. Catalano, P.M., E.D. Tyzbir, and E.A. Sims, Incidence and significance of islet cell antibodies in women with previous gestational diabetes. Diabetes Care, 1990. 13(5): p. 478-82. 13. Kousta, E., et al., Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes. Diabet Med, 2001. 18(8): p. 683-4. 14. Solomon, C.G., et al., A prospective study of pregravid determinants of gestational diabetes mellitus. Jama, 1997. 278(13): p. 1078-83. 15. Gilmartin, A.B.H., S.H. Ural, and J.T. Repke, Gestational Diabetes Mellitus. Reviews in Obstetrics and Gynecology, 2008. 1(3): p. 129-134. 16. Xiang, A.H., et al., Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus. Diabetologia, 2011. 54(12): p. 3016-21. 17. Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes Care, 1998. 21 Suppl 2: p. B1-167. 18. Satodiya, M., et al., Comparison of One-Step Versus Two-Step Screening for Diagnosis of GDM in Indian Population: A Randomized Controlled Trial. J Obstet Gynaecol India, 2017. 67(3): p. 190-195. 19. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care, 2010. 33(3): p. 676-682. 20. 2. Classification and Diagnosis of Diabetes. Diabetes Care, 2017. 40(Supplement 1): p. S11-S24. 21. Berggren, E.K., et al., National Diabetes Data Group vs Carpenter-Coustan criteria to diagnose gestational diabetes. American Journal of Obstetrics and Gynecology, 2011. 205(3): p. 253.e1-253.e7. 22. Magee, M.S., et al., Influence of diagnostic criteria on the incidence of gestational diabetes and perinatal morbidity. Jama, 1993. 269(5): p. 609-15. 23. Carpenter, M.W. and D.R. Coustan, Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol, 1982. 144(7): p. 768-73. 24. Ogunyemi, D.A., et al., Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). Diabet Med, 2011. 28(8): p. 976-86. 25. Thapa, P., et al., Gestational Diabetes Mellitus - A Public Health Concern in Rural Communities of Nepal. J Nepal Health Res Counc, 2015. 13(31): p. 175-81. 26. Landon, M.B., et al., A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes. The New England journal of medicine, 2009. 361(14): p. 1339-1348. 27. Crowther, C.A., et al., Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med, 2005. 352(24): p. 2477-86. 28. Blumer, I., et al., Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2013. 98(11): p. 4227-49. 29. Jovanovic-Peterson, L., et al., Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol, 1991. 164(1 Pt 1): p. 103-11. 30. Jovanovic, L., Role of diet and insulin treatment of diabetes in pregnancy. Clin Obstet Gynecol, 2000. 43(1): p. 46-55. 31. Rasmussen, K.M., P.M. Catalano, and A.L. Yaktine, New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. Curr Opin Obstet Gynecol, 2009. 21(6): p. 521-6. 32. Goldenberg, R.L., et al., Epidemiology and causes of preterm birth. Lancet, 2008. 371(9606): p. 75-84. 33. Metzger, B.E., et al., Hyperglycemia and adverse pregnancy outcomes. N Engl J Med, 2008. 358(19): p. 1991-2002. 34. Linderkamp, O., Blood Viscosity of the Neonate. NeoReviews, 2004. 5(10): p. e406-e416. 35. Pedersen, J., Diabetes and pregnancy; blood sugar of newborn infants during fasting and glucose administration. Ugeskr Laeger, 1952. 114(21): p. 685. 36. Henriksen, T., The macrosomic fetus: a challenge in current obstetrics. Acta Obstet Gynecol Scand, 2008. 87(2): p. 134-45. 37. Kc, K., S. Shakya, and H. Zhang, Gestational diabetes mellitus and macrosomia: a literature review. Ann Nutr Metab, 2015. 66 Suppl 2: p. 14-20. 38. Mitanchez, D., Foetal and neonatal complications in gestational diabetes: perinatal mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal complications. Diabetes Metab, 2010. 36(6 Pt 2): p. 617-27. 39. Mitanchez, D., A. Burguet, and U. Simeoni, Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health. J Pediatr, 2014. 164(3): p. 445-50. 40. Ullmo, S., et al., Pathologic ventricular hypertrophy in the offspring of diabetic mothers: a retrospective study. Eur Heart J, 2007. 28(11): p. 1319-25. 41. Pettitt, D.J., et al., Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care, 1993. 16(1): p. 310-4. 42. Rabinovitch, A., Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes, 1994. 43(5): p. 613-21. 43. Commins, S.P., L. Borish, and J.W. Steinke, Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol, 2010. 125(2 Suppl 2): p. S53-72. 44. Rengarajan, J., S.J. Szabo, and L.H. Glimcher, Transcriptional regulation of Th1/Th2 polarization. Immunol Today, 2000. 21(10): p. 479-83. 45. Ategbo, J.M., et al., Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab, 2006. 91(10): p. 4137-43. 46. Brelje, T.C., et al., Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology, 1993. 132(2): p. 879-87. 47. Handwerger, S. and M. Freemark, The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab, 2000. 13(4): p. 343-56. 48. Okuno, S., et al., Decreased expression of the GLUT4 glucose transporter protein in adipose tissue during pregnancy. Horm Metab Res, 1995. 27(5): p. 231-4. 49. White, M.F., et al., A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem, 1988. 263(6): p. 2969-80. 50. Aguirre, V., et al., The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem, 2000. 275(12): p. 9047-54. 51. Gao, Z., et al., Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem, 2002. 277(50): p. 48115-21. 52. Li, Y., et al., Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem, 2004. 279(44): p. 45304-7. 53. Tzatsos, A. and K.V. Kandror, Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol, 2006. 26(1): p. 63-76. 54. Um, S.H., et al., Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature, 2004. 431(7005): p. 200-5. 55. Barbour, L.A., et al., Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance postpartum. J Clin Endocrinol Metab, 2011. 96(5): p. 1431-41. 56. Garvey, W.T., et al., Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest, 1998. 101(11): p. 2377-86. 57. Coughlan, M.T., et al., Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med, 2001. 18(11): p. 921-7. 58. Gao, X.L., H.X. Yang, and Y. Zhao, Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J (Engl), 2008. 121(8): p. 701-5. 59. Mosmann, T.R. and R.L. Coffman, Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol, 1989. 46: p. 111-47. 60. Ashkar, A.A., J.P. Di Santo, and B.A. Croy, Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med, 2000. 192(2): p. 259-70. 61. Sinzato, Y.K., et al., Plasma concentrations and placental immunostaining of interleukin-10 and tumor necrosis factor-alpha as predictors of alterations in the embryo-fetal organism and the placental development of diabetic rats. Braz J Med Biol Res, 2011. 44(3): p. 206-11. 62. Wu, M.-Y., et al., Increase in the Production of Interleukin-10 Early After Implantation is Related to the Success of Pregnancy. American Journal of Reproductive Immunology, 2003. 46(6): p. 386-392. 63. Hennessy, A., et al., A deficiency of placental IL-10 in preeclampsia. J Immunol, 1999. 163(6): p. 3491-5. 64. Ozcaka, O., et al., Clinical periodontal status and inflammatory cytokines in gestational diabetes mellitus. Arch Oral Biol, 2016. 72: p. 87-91. 65. Mosmann, T.R., et al., Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol, 1990. 145(9): p. 2938-45. 66. Zhu, Y.P., et al., AMP-activated protein kinase regulates IL-10-mediated antiinflammatory signaling pathways in macrophages. Journal of immunology (Baltimore, Md. : 1950), 2015. 194(2): p. 584-594. 67. Thaxton, J.E. and S. Sharma, Interleukin-10: a multi-faceted agent of pregnancy. Am J Reprod Immunol, 2010. 63(6): p. 482-91. 68. Moore, K.W., et al., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001. 19: p. 683-765. 69. Choi, Y.K. and J. Kwak-Kim, Cytokine gene polymorphisms in recurrent spontaneous abortions: a comprehensive review. Am J Reprod Immunol, 2008. 60(2): p. 91-110. 70. de Lima, T.H., et al., Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens Res, 2009. 32(7): p. 565-9. 71. Vural, P., et al., Tumor necrosis factor alpha, interleukin-6 and interleukin-10 polymorphisms in preeclampsia. J Obstet Gynaecol Res, 2010. 36(1): p. 64-71. 72. Mattar, R., E. de Souza, and S. Daher, Preterm delivery and cytokine gene polymorphisms. J Reprod Med, 2006. 51(4): p. 317-20. 73. Babel, N., et al., Analysis of tumor necrosis factor-alpha, transforming growth factor-beta, interleukin-10, IL-6, and interferon-gamma gene polymorphisms in patients with chronic periodontitis. J Periodontol, 2006. 77(12): p. 1978-83. 74. Turner, D.M., et al., An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 1997. 24(1): p. 1-8. 75. Rees, L.E., et al., The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci, 2002. 59(3): p. 560-9. 76. Steinke, J.W., et al., Functional Analysis of −571 IL-10 Promoter Polymorphism Reveals a Repressor Element Controlled by Sp1. The Journal of Immunology, 2004. 173(5): p. 3215-3222. 77. Babel, N., et al., Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease. J Nephrol, 2006. 19(6): p. 802-7. 78. Mok, C.C., et al., Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum, 1998. 41(6): p. 1090-5. 79. Koch, W., et al., Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis, 2001. 159(1): p. 137-44. 80. Tegoshi, H., et al., Polymorphisms of interferon-gamma gene CA-repeat and interleukin-10 promoter region (-592A/C) in Japanese type I diabetes. Hum Immunol, 2002. 63(2): p. 121-8. 81. Edwards-Smith, C.J., et al., Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology, 1999. 30(2): p. 526-30. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72014 | - |
dc.description.abstract | 妊娠糖尿病(Gestational diabetes mellitus, GDM)是在妊娠時期最常見的代謝疾病,而抗發炎性細胞激素Interleukin-10(IL-10)具有穩定與維持妊娠發育的重要功能,根據先前研究指出在IL-10基因啟動子區域三個位置-592 C>A (rs1800872)、-819 C>T (rs1800871)和-1082 A>G (rs1800896)的單核苷酸多型性(single nucleotide polymorphisms, SNPs)會影響IL-10表現量,但這三個位置的多型性對於妊娠糖尿病發生的影響尚未清楚,我們除了研究常見-592、-819和-1082三個位置外,還探討未被發表過3388 A>C (rs3021094)位置,希望藉由分析這些SNPs變異可以找出對於IL-10表現量影響與妊娠糖尿病發生的相關性。
我們的研究對象依據75公克葡萄糖口服耐性測試(oral glucose tolerance tests, OGTT)分為100位受試者是健康對照組,42位受試者是妊娠糖尿病患者,使用卡方檢定(Chi-square test)或是費雪精確性檢定(Fisher’s exact test)分析基因型與對偶基因頻率,勝算比(Odds ratio, OR)與95%信賴區間(confidence interval, CI)評估妊娠糖尿病發生的風險值;而IL-10 SNPs基因型與IL-10表現量關係,使用ELISA測量母血中IL-10濃度,以無母數Kruskal-Wallis H test或是Mann-Whitney U test統計分析。 研究結果顯示,IL-10 3388 A>C在顯性模式(AA+CA versus CC)下,屬於基因型AA+CA與對偶基因A在妊娠糖尿病所占的比例顯著高於對照組(P < 0.05),並且具有較高風險發生妊娠糖尿病(OR = 2.88,95% CI [1.03-8.07];OR = 1.85,95%CI [1.10-3.12]),而比較-592 C>A、-819 C>T和-1082 A>G的基因型與對偶基因頻率在妊娠糖尿病以及對照組間沒有顯著差異(P ≥ 0.05);IL-10表現量方面,當-592 C>A基因型是CC、-819 C>T基因型是CC與3388 A>C基因型是AA時,IL-10表現量有顯著較高的情形(P < 0.05),但比較-1082 A>G基因型沒有顯著差異(P ≥ 0.05)。 總而言之,在IL-10 3388 A>C (rs3021094)的位置,對於IL-10表現量與妊娠糖尿病發生都有顯著相關,未來有機會可以考慮納入預測妊娠糖尿病發生的指標之一。 | zh_TW |
dc.description.abstract | Gestational diabetes mellitus (GDM) is the most common metabolic disease in pregnant women. Interleukin-10 (IL-10) is an important anti-inflammatory cytokines for pregnancy maintenance and development. Previous studies indicated that three IL-10 promoter region single nucleotide polymorphisms (SNPs) at position -592 C>A (rs1800872), -819 C>T (rs1800871), and -1082 A>G (rs1800896) play an important role in IL-10 secretion capacity, but it’s genetic polymorphisms in GDM are unknown. In addition to the three common SNPs -592, -819, and -1082, we also explore a rare to be reported position 3388 A>C (rs3021094). We examined whether these SNPs variant are associated with IL-10 production and GDM susceptibility.
Our case-control study included 100 healthy controls and 42 women with GDM grouped according to 75g oral glucose tolerance tests (OGTT). The polymorphisms of genotype and allele frequencies were analyzed by Chi-square test or Fisher’s exact test. Odds ratio (OR) and 95% confidence interval (CI) were used to explain relative risk of GDM. Maternal plasma IL-10 levels were measured by ELISA and associated with the polymorphisms of genotype were analyzed by non-parametric Kruskal-Wallis H test or Mann Whitney U test. In the dominant model (AA+CA versus CC) of IL-10 3388 A>C, AA+CA genotype and A allele frequencies were significantly higher in cases compared with controls (P < 0.05), suggesting significant association with risk of GDM (OR = 2.88, 95% CI [1.03-8.07]; OR = 1.85, 95%CI [1.10-3.12]). No significant difference of -592 C>A, -819 C>T, and -1082 A>G were observed between cases and controls (P > 0.05). CC genotype of -592 C>A, CC genotype of -819 C>T, and AA genotype of 3388 A>C were all significantly higher IL-10 plasma level production compared with other genotypes (P < 0.05), suggesting significant association with IL-10 high-level production. No significant difference of -1082 A>G were observed (P > 0.05). In conclusion, SNP at position IL-10 3388 A>C was significantly associated with the risk of GDM and IL-10 plasma level high production. IL-10 3388 A>C has potential for use as a predictive maker for GDM. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:19:10Z (GMT). No. of bitstreams: 1 ntu-107-P05448013-1.pdf: 3932374 bytes, checksum: ac37b10edc6541eaf75e48b201109bf4 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 目錄
口試委員審定書..………………………………………………………………............i 誌謝………………………………………………………………………………..........ii 摘要………………………………………………………………………………….....iii 英文摘要…………………………………………………………………………..........v 第一章、緒論……………………………………………………………………...........1 1.1 前言…………………………………………………………………….........1 1.2 妊娠糖尿病簡介……………………………………………………….........1 1.2.1 妊娠糖尿病的病因.................................................................................1 1.2.2 妊娠糖尿病的診斷…….........................................................................3 1.2.3 妊娠糖尿病的治療………….................................................................4 1.2.4 妊娠糖尿病的影響……………...………………..................................5 1.3 細胞激素IL-10與妊娠糖尿病的相關性..........................................................7 1.3.1 妊娠糖尿病與胰島素阻抗作用相關的代謝途徑.................................7 1.3.2 細胞激素IL-10與妊娠糖尿病相關研究...............................................9 1.4 細胞激素IL-10與IL-10基因多型性..............................................................10 1.5 研究目的...............................................................................................12 第二章、研究方法與材料……….........................................................................13 2.1 研究對象.....................................................................................................13 2.2 血液檢體萃取基因組DNA (genomic DNA)..................................................13 2.3 IL-10基因SNPs分析....................................................................................15 2.4 細胞激素IL-10表現量分析............................................................................15 2.5 統計分析......................................................................................................17 2.5.1 研究對象統計分析...............................................................................17 2.5.2 IL-10基因SNPs對於妊娠糖尿病發生風險與IL-10表現量分析.................17 第三章、結果…....………………………………....................................19 3.1 研究對象........................................................................................................19 3.2 IL-10基因SNPs對於妊娠糖尿病發生風險分析................................................19 3.2.1 IL-10基因-592 C>A (rs1800872)............................................................19 3.2.2 IL-10基因-819 C>T (rs1800871).........................................................20 3.2.3 IL-10基因-1082 A>G (rs1800896)......................................................20 3.2.4 IL-10基因3388 A>C (rs3021094).......................................................20 3.3 妊娠糖尿病與IL-10表現量的相關性.............................................................21 3.4 IL-10基因SNPs對於細胞激素IL-10表現量影響析.........................................21 3.4.1 IL-10基因-592 C>A (rs1800872).........................................................21 3.4.2 IL-10基因-819 C>T (rs1800871)..........................................................22 3.4.3 IL-10基因-1082 A>G (rs1800896)......................................................22 3.4.4 IL-10基因3388 A>C (rs3021094).......................................................22 第四章、討論.....................................................................................................24 參考文獻............................................................................................................28 圖目錄 圖一、本研究流程圖...........................................................................................35 圖二、葡萄糖吸收與胰島素訊息傳遞途徑,妊娠糖尿病胰島素阻抗作用發生的機 制(Barbour, L.A., et al., 2007).......................................................................36 圖三、細胞激素IL-10轉錄作用途徑(Zhu, Y.P., et al.,2015)...................................37 圖四、我們分析的四個SNPs分別為-592 C>A (rs1800872)、-819 C>T(rs1800871)、 -1082 A>G (rs1800896)和3388 A>C (rs3021094)在IL-10基因的位置.........38 圖五、IL-10濃度對於妊娠糖尿病的敏感度與1-特異度相對應的ROC線圖.........39 表目錄 表一、IL-10基因SNPs PCR反應,所使用的引子序列.......................................40 表二、研究對象總共有142位受試者,其中100位受試者為非妊娠糖尿病(對照組), 42位受試者為妊娠糖尿病,比較身高、體重、BMI和糖化血色...等..................41 表三、分析-592 C>A (rs1800872)、-819 C>T (rs1800871)、-1082 A>G (rs1800896)和3388 A>C (rs3021094)基因型與對偶基因對於妊娠糖尿病發生的相關性..........................................................................................................42 表四、IL-10表現量以濃度6.5 pg/mL做區分,對照組與妊娠糖尿病患者兩者的IL-10表現量比較.........................................................................................................43 表五、分析124位受試者的IL-10 SNPs基因型與IL-10表現量的相關性...............44 | |
dc.language.iso | zh-TW | |
dc.title | 妊娠糖尿病與IL-10基因多型性之探討 | zh_TW |
dc.title | Polymorphism of Interleukin-10 gene in Gestational Diabetes Mellitus | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周祖述(Tzuu-Shuh Jou),李建南(Chien-Nan Lee) | |
dc.subject.keyword | 妊娠糖尿病,Interleukin-10 (IL-10),單核?酸多型性,-592 C>A (rs1800872),-819 C>T (rs1800871),-1082 A>G (rs1800896),3388 A>C (rs3021094), | zh_TW |
dc.subject.keyword | Gestational diabetes mellitus (GDM),Interleukin-10 (IL-10),single nucleotide polymorphisms (SNPs),-592 C>A (rs1800872),-819 C>T (rs1800871),-1082 A>G (rs1800896),3388 A>C (rs3021094), | en |
dc.relation.page | 44 | |
dc.identifier.doi | 10.6342/NTU201803884 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 3.84 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。